Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:AUTLNASDAQ:DBVTNASDAQ:MGTXNASDAQ:REPL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$11.00-3.0%$16.28$7.10▼$29.70$228.25M0.84239,814 shs304,948 shsAUTLAutolus Therapeutics$4.48-1.8%$5.84$1.61▼$7.45$1.19B1.91.51 million shs1.72 million shsDBVTDBV Technologies$0.71+6.0%$0.79$0.65▼$2.37$136.07M0.7550,902 shs116,976 shsMGTXMeiraGTx$4.93-1.8%$5.91$3.49▼$8.35$316.61M1.29155,245 shs164,022 shsREPLReplimune Group$6.42$7.91$5.89▼$24.81$394.12M1.211.34 million shs1.16 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%-1.65%-29.39%+31.25%+21.94%AUTLAutolus Therapeutics+0.88%-6.94%-27.85%-17.39%+153.33%DBVTDBV Technologies-3.18%-5.12%-17.11%-25.00%-57.96%MGTXMeiraGTx-1.38%-8.23%-21.07%-24.05%-11.46%REPLReplimune Group-0.47%-9.83%-21.71%-18.32%-62.78%Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0707 of 5 stars3.52.00.04.83.12.50.0AUTLAutolus Therapeutics2.8234 of 5 stars3.43.00.00.02.53.30.6DBVTDBV Technologies1.4493 of 5 stars3.21.00.00.00.03.31.3MGTXMeiraGTx3.9446 of 5 stars3.54.00.04.80.01.70.6REPLReplimune Group4.4841 of 5 stars3.51.00.04.53.73.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67215.15% UpsideAUTLAutolus Therapeutics2.80Moderate Buy$8.1682.14% UpsideDBVTDBV Technologies2.33Hold$5.00608.72% UpsideMGTXMeiraGTx3.00Buy$25.67420.62% UpsideREPLReplimune Group3.00Buy$37.67486.71% UpsideCurrent Analyst RatingsLatest REPL, DBVT, ADVM, MGTX, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/9/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $11.003/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/18/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/14/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M63.40N/AN/A$8.26 per share1.33AUTLAutolus Therapeutics$1.70M700.80N/AN/A$0.64 per share7.00DBVTDBV Technologies$15.73M8.65N/AN/A$0.73 per share0.97MGTXMeiraGTx$14.02M22.58N/AN/A$2.17 per share2.27REPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)AUTLAutolus Therapeutics-$208.38M-$1.19N/AN/AN/AN/A-105.75%-49.25%5/2/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.48N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)REPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)Latest REPL, DBVT, ADVM, MGTX, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A3/14/2024Q4 2023AUTLAutolus Therapeutics-$0.26-$0.44-$0.18-$0.44N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million 2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13AUTLAutolus TherapeuticsN/A6.156.15DBVTDBV TechnologiesN/A4.264.26MGTXMeiraGTx0.622.382.38REPLReplimune Group0.1612.4012.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%AUTLAutolus Therapeutics72.83%DBVTDBV Technologies71.74%MGTXMeiraGTx67.48%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%AUTLAutolus Therapeutics25.70%DBVTDBV Technologies0.60%MGTXMeiraGTx9.70%REPLReplimune Group20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableAUTLAutolus Therapeutics463265.93 million197.58 millionOptionableDBVTDBV Technologies104192.87 million191.71 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableREPLReplimune Group28461.39 million48.74 millionOptionableREPL, DBVT, ADVM, MGTX, and AUTL HeadlinesSourceHeadlineVontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 19 at 5:37 AMHead to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)americanbankingnews.com - April 13 at 1:30 AMVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 10 at 4:00 AMInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 7 at 5:00 PMReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 4 at 8:00 AMFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingbizjournals.com - March 30 at 9:59 AMReplimune appoints new CEO ahead of drug applicationuk.investing.com - March 29 at 12:50 AMPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealbizjournals.com - March 28 at 9:48 AMReplimune Names Sushil Patel as CEO in Broader Shakeupmarketwatch.com - March 26 at 12:12 PMReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOmarkets.businessinsider.com - March 26 at 12:12 PMReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitionsglobenewswire.com - March 26 at 7:30 AMREPL Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:31 PMREPL Mar 2024 10.000 putfinance.yahoo.com - March 15 at 4:28 PMHow Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%zacks.com - March 11 at 10:56 AMWhat Makes Replimune Group, Inc. (REPL) a New Buy Stockzacks.com - March 8 at 1:01 PMReplimune to Present at the American Association for Cancer Research Annual Meeting 2024finance.yahoo.com - March 6 at 7:31 PMReplimune to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - March 5 at 10:04 AMWall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?zacks.com - February 23 at 10:56 AMPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trialsmarkets.businessinsider.com - February 15 at 6:48 PMAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 9 at 7:41 AMReplimune Group Is Worried About This – Should You Be Worried Too?msn.com - February 9 at 7:41 AMReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runwayfinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL)investing.com - February 8 at 12:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit Upside3 High Dividend Stocks to Replace Lower Savings Yields AheadApril 9, 2024 9:15 AMView 3 High Dividend Stocks to Replace Lower Savings Yields AheadAll Headlines Company DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Autolus TherapeuticsNASDAQ:AUTLAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.